RLMD RELMADA THERAPEUTICS, INC.

Nasdaq relmada.com


$ 2.01 $ 0.02 (1.01 %)    

Friday, 17-Oct-2025 15:58:51 EDT
QQQ $ 604.41 $ 6.27 (1.05 %)
DIA $ 462.17 $ 2.39 (0.52 %)
SPY $ 664.97 $ 4.85 (0.74 %)
TLT $ 91.12 $ -0.05 (-0.05 %)
GLD $ 389.35 $ -8.41 (-2.12 %)
$ 2.01
$ 1.98
$ 1.87 x 100
$ 2.01 x 20
$ 1.81 - $ 2.01
$ 0.24 - $ 3.98
201,390
na
66.72M
$ 1.44
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-24-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 11-13-2019 09-30-2019 10-Q
24 09-24-2019 06-30-2019 10-K
25 05-15-2019 03-31-2019 10-Q
26 02-13-2019 12-31-2018 10-Q
27 11-13-2018 09-30-2018 10-Q
28 09-28-2018 06-30-2018 10-K
29 05-14-2018 03-31-2018 10-Q
30 02-12-2018 12-31-2017 10-Q
31 11-14-2017 09-30-2017 10-Q
32 09-28-2017 06-30-2017 10-K
33 05-15-2017 03-31-2017 10-Q
34 02-10-2017 12-31-2016 10-Q
35 11-10-2016 09-30-2016 10-Q
36 09-09-2016 06-30-2016 10-K
37 05-09-2016 03-31-2016 10-Q
38 02-05-2016 12-31-2015 10-Q
39 11-06-2015 09-30-2015 10-Q
40 09-11-2015 06-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 relmada-therapeutics-cmo-raj-s-pruthi-purchases-55000-shares-in-open-market-on-august-29-2025

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), pur...

 relmada-therapeutics-q2-eps-030-misses-002-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate o...

 relmada-therapeutics-terminates-license-agreement-with-dr-charles-e-inturrisi--dr-paolo-manfredi-ends-esmethadone-development-program

-SEC Filing

 relmada-therapeutics-q1-gaap-eps-058-misses-052-estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate o...

 relmada-therapeutics-initial-data-from-phase-2-study-of-ndv-01-shows-strong-clinical-activity-in-bcg-nave-and-bcg-unresponsive-patients

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION